Population Pharmacokinetics of Cariprazine and its Major Metabolites

BACKGROUND AND OBJECTIVES: Cariprazine, a dopamine D(3)-preferring D(3)/D(2) receptor partial agonist, is approved for the treatment of adults with schizophrenia (1.5–6 mg/day) and manic/mixed (3–6 mg/day) episodes associated with bipolar I disorder. This population pharmacokinetic analysis describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Periclou, Antonia, Phillips, Luann, Ghahramani, Parviz, Kapás, Margit, Carrothers, Timothy, Khariton, Tatiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811992/
https://www.ncbi.nlm.nih.gov/pubmed/33141308
http://dx.doi.org/10.1007/s13318-020-00650-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811992/
https://www.ncbi.nlm.nih.gov/pubmed/33141308
http://dx.doi.org/10.1007/s13318-020-00650-4

Ejemplares similares